Publication | Closed Access

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

Hematological MalignancyPsc 833Phase I/ii StudyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderPharmacologyPharmacotherapyOncologyRadiation OncologyMdr Modulator ValspodarCancer ResearchMyeloid Neoplasia